CTNM Latest Press Releases

-- July 30, 2026 --

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones Business Wire 4:05 PM

-- June 30, 2026 --

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry Business Wire 4:05 PM

-- June 1, 2026 --

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference Business Wire 4:05 PM

-- May 15, 2026 --

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM

-- May 12, 2026 --

Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference Business Wire 4:05 PM

-- May 11, 2026 --

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference Business Wire 4:05 PM

-- May 5, 2026 --

Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones Business Wire 4:05 PM

-- May 1, 2026 --

Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM

-- April 30, 2026 --

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain Business Wire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software